Better Understanding the Function of Critical or Underexploited Ubiquitin Ligases, Improving Specificity & Accelerating Ligand Discovery & Optimization to Develop E3-Targeting Therapeutics for Successful Protein Degradation or Modulation

ARPIL 26-28, 2022 | BOSTON

From discovery to clinical development the field of protein degradation is booming with excitement, investment and new companies joining the effort to successfully degrade unwanted or undrugged targets, with key roles in a broad range of diseases from oncology to CNS, through to autoimmune. 

Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases, understand the structure and function and accelerate ligand screening, and optimize with new and improved tools, making this process lengthy and risky for biopharma. 

The 2nd Ligase Targeting Drug Development Summit returns with new insight and data from pioneers in the field to delve deep into ligase biology, assays to investigate functions as well as screening tools for optimum ligand identification and validation. This forum will provide an unrivalled meeting-point for industry leaders, in order to strategically accelerate and de-risk the process of identifying, validating and therapeutically leveraging cell and tissue specific Ubiquitin E3 ligases for degradation or modulation of targets of interest. 

Experienced Attendees


Dedicated Sessions

Interactive Workshops

Deep Dive
Focus Day

Snapshot of Who Attended in 2021


Group Discounts Available

Maximize value for money using special team discounts:

10% discount - 3 delegates
15% discount - 5 delegates
20% discount - 7+ delegates

What Did Our 2021 Speakers Have To Say?

"Understanding E3 ligases in full molecular detail is fast becoming one of the most important areas to accelerate in drug development. I look forward to hearing from expert colleagues on the many inventive efforts in this crucial space" – Benedict Cross, Chief Technology Officer, PhoreMost

"This meeting enables an exchange of novel ideas for experts and novices in the field that eventually enable us to progress and discover novel therapeutic opportunities" - Claudio Thoma, Senior Principal Scientist, Novartis Institutes for Biomed Research

"A chance to share exciting research and ideas with peers and experts in this evolving area of drug discovery is an opportunity not to be missed" – Joe Patel, Senior Director, C4 Therapeutics

"As a young group leader this opportunity is of great interest to further develop key contacts in this field, to share our current research and to offer our resources through collaboration" – Rebecca Feltham Laboratory Head The Walter and Eliza Hall Institute of Medical Research

Other Events In The Undruggable Series